A clinical trial of Azelastine in recurrent aphthous ulceration, with an analysis of its actions on leukocytes.


Azelastine (azelastine hydrochloride) was orally administered to 43 patients with recurrent aphthous ulcers (RAU), and its clinical effects and in vitro influence on leukocytes were examined. During at least 6 months after drug treatment, no oral ulcers occurred in 7 patients, and an improvement of the oral condition was exhibited in all except 4 of the… (More)


  • Presentations referencing similar topics